Home › NDC Lookup › RxCUI directory › RxCUI 1736863

3 ML insulin glargine 100 UNT/ML Pen Injector [Basaglar] — RxCUI 1736863

Name: 3 ML insulin glargine 100 UNT/ML Pen Injector [Basaglar] (RxCUI 1736863)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 1736863 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1736863

Official name3 ML insulin glargine 100 UNT/ML Pen Injector [Basaglar]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known as3 ML Basaglar 100 UNT/ML Pen Injector; Basaglar KwikPen 100 UNT/ML in 3 ML Pen Injector; Basaglar 300 UNT per 3 ML Pen Injector

FDA products mapped2

Package NDCs mapped3

Reported Medicaid activity (SDUD)332,820 prescriptions · 46 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Insulin Glargine (rDNA origin) Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Insulin glargine is a long-acting insulin that works as a steady background insulin for your body throughout the day. It helps move sugar from your bloodstream into your cells for...
What exactly does insulin glargine do, and why do I need it?
You inject insulin glargine once a day, under the skin (not into a vein or muscle), in your abdomen, thigh, or upper arm. The key is to pick the same time every day and stick to it...
Low blood sugar — called hypoglycemia — is the most common and most serious risk. Signs include shakiness, sweating, dizziness, confusion, rapid heartbeat, or sudden hunger. Mild c...

📖 Read our full Insulin Glargine (rDNA origin) Injection guide →

🕸️ Concept Web — How 3 ML insulin glargine 100 UNT/ML Pen Injector [B... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 3 ML insulin glargine 100 UNT/ML Pen Injector [Basaglar] RxCUI 1736863 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Insulin glargine 274783 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Basaglar 1736859 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Insulin glargine Pen Injector 1653497 SCDF
- Insulin glargine Injectable Product 1157459 SCDG
- Insulin glargine Pen Injector [Basaglar] 1736861 SBDF
- Basaglar Injectable Product 1736862 SBDG
- Pen Injector 1649571 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 3 ML insulin glargine 100 UNT/ML Pen Injector 847230 SCD
- Insulin glargine 100 UNT/ML 343226 SCDC
- Insulin glargine 100 UNT/ML [Basaglar] 1736860 SBDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

3 ML insulin glargine 100 UNT/ML Pen Injector SCD · 847230
Insulin glargine 100 UNT/ML SCDC · 343226
Insulin glargine Pen Injector SCDF · 1653497
Insulin glargine Injectable Product SCDG · 1157459

Brand-Name Concepts

Insulin glargine 100 UNT/ML [Basaglar] SBDC · 1736860
Insulin glargine Pen Injector [Basaglar] SBDF · 1736861
Basaglar Injectable Product SBDG · 1736862
Basaglar BN · 1736859

📦 FDA Products & Package NDCs

2 products · 3 package NDCs

3 package NDCs map to RxCUI 1736863 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00002-7715-59	5 SYRINGE in 1 CARTON (0002-7715-59) / 3 mL in 1 SYRINGE (0...	BASAGLAR KwikPen	Eli Lilly and Company	2016-06-17
00002-7715-63	1 SYRINGE in 1 CARTON (0002-7715-63) / 3 mL in 1 SYRINGE	BASAGLAR KwikPen	Eli Lilly and Company	2016-07-15
00002-8214-05	5 SYRINGE in 1 CARTON (0002-8214-05) / 3 mL in 1 SYRINGE (0...	BASAGLAR Tempo Pen	Eli Lilly and Company	2019-11-15

Observed labelers: Eli Lilly and Company (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.

Per ml · median

$20.9420

Range $20.9291–$20.9549 · middle 50% $20.9356–$20.9485 · 2 NDCs

Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.